97 related articles for article (PubMed ID: 10048755)
1. Are topoisomerase II inhibitor-induced micronuclei in vitro a predictive marker for the compounds' ability to cause secondary leukemias after treatment?
Stopper H; Boos G; Clark M; Gieseler F
Toxicol Lett; 1999 Jan; 104(1-2):103-10. PubMed ID: 10048755
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin.
Olaharski AJ; Mondrala ST; Eastmond DA
Mutat Res; 2005 Apr; 582(1-2):79-86. PubMed ID: 15781213
[TBL] [Abstract][Full Text] [Related]
3. Genotoxicity of several clinically used topoisomerase II inhibitors.
Boos G; Stopper H
Toxicol Lett; 2000 Jul; 116(1-2):7-16. PubMed ID: 10906417
[TBL] [Abstract][Full Text] [Related]
4. Concentration-response studies of the chromosome-damaging effects of topoisomerase II inhibitors determined in vitro using human TK6 cells.
Gollapudi P; Bhat VS; Eastmond DA
Mutat Res Genet Toxicol Environ Mutagen; 2019 May; 841():49-56. PubMed ID: 31138411
[TBL] [Abstract][Full Text] [Related]
5. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.
Willmore E; Errington F; Tilby MJ; Austin CA
Biochem Pharmacol; 2002 May; 63(10):1807-15. PubMed ID: 12034365
[TBL] [Abstract][Full Text] [Related]
6. Micronuclei in neonatal lymphocytes treated with the topoisomerase II inhibitors amsacrine and etoposide.
Slavotinek A; Perry PE; Sumner AT
Mutat Res; 1993 Nov; 319(3):215-22. PubMed ID: 7694143
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human DNA topoisomerase II by hydroquinone and p-benzoquinone, reactive metabolites of benzene.
Hutt AM; Kalf GF
Environ Health Perspect; 1996 Dec; 104 Suppl 6(Suppl 6):1265-9. PubMed ID: 9118903
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal aberration and micronucleus studies of two topoisomerase (II) targeting anthracyclines.
Khan F; Sherwani AF; Afzal M
J Environ Biol; 2009 May; 30(3):409-12. PubMed ID: 20120468
[TBL] [Abstract][Full Text] [Related]
9. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.
Anderson RD; Berger NA
Mutat Res; 1994 Aug; 309(1):109-42. PubMed ID: 7519727
[TBL] [Abstract][Full Text] [Related]
10. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
Leukemia; 1996 Jul; 10 Suppl 3():S46-S49. PubMed ID: 8656700
[TBL] [Abstract][Full Text] [Related]
12. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
[TBL] [Abstract][Full Text] [Related]
13. Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells.
Wang L; Roy SK; Eastmond DA
Mutat Res; 2007 Mar; 616(1-2):70-82. PubMed ID: 17174356
[TBL] [Abstract][Full Text] [Related]
14. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
Wang L; Eastmond DA
Environ Mol Mutagen; 2002; 39(4):348-56. PubMed ID: 12112387
[TBL] [Abstract][Full Text] [Related]
15. Formation of micronuclei and inhibition of topoisomerase II in the comet assay in mammalian cells with altered DNA methylation.
Stopper H; Eckert I; Wagener P; Schulz WA
Recent Results Cancer Res; 1997; 143():183-93. PubMed ID: 8912419
[No Abstract] [Full Text] [Related]
16. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
Leukemia; 1996 Jul; 10(7):1177-80. PubMed ID: 8683999
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
Suzuki H; Tarumoto Y; Ohsawa M
Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-a]indole derivatives and their growth inhibitory activities.
Umemura K; Mizushima T; Katayama H; Kiryu Y; Yamori T; Andoh T
Mol Pharmacol; 2002 Oct; 62(4):873-80. PubMed ID: 12237334
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer cell lines by a marine microalgal polysaccharide.
Umemura K; Yanase K; Suzuki M; Okutani K; Yamori T; Andoh T
Biochem Pharmacol; 2003 Aug; 66(3):481-7. PubMed ID: 12907247
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II inhibition by myeloperoxidase-activated hydroquinone: a potential mechanism underlying the genotoxic and carcinogenic effects of benzene.
Eastmond DA; Mondrala ST; Hasegawa L
Chem Biol Interact; 2005 May; 153-154():207-16. PubMed ID: 15935818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
